ASCO GU 2025: New Drug CBP-1018 Shows Promise for Advanced Prostate Cancer in Clinical Trial
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxUpdate Phase 1: Mevrometostat Shows Promise in Prostate Cancer by Targeting EZH2
/in Clinical Trial, Metastatic, Phase 1/by MaxPioneering Korean Trial Combines Radioligand Therapy and Immunotherapy for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Clinical Trial Recruiting: HLD-0915 a RIPTAC (Regulated Induced Proximity Targeting Chimera)
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial Will Soon Start Recruiting: ACE-232 a Promising Inhibitor of CYP11A1
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: CRB-701, A Promising Antibody-Drug Conjugate Targeting Nectin-4
/in Clinical Trial, Metastatic, Phase 1/by MaxLY4052031 and LY4101174: Other 2 Nectin-4-Targeting Therapy
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule October 27, 2025
- Helicon Degraders Show a New Path in Prostate Cancer Therapy October 27, 2025
- UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer October 27, 2025
- Newsletter 43/2025 October 26, 2025